8-K - CRISPR Therapeutics AG | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

CRISPR Therapeutics AG announced on March 10, 2026, that it commenced a private offering, as disclosed in a press release filed as Exhibit 99.1 with the Form 8-K. This event under Item 8.01 provides investors with information on the company's financing activities.

Key Takeaways

1Company issued press release on March 10, 2026

2Commenced private offering

3Press release filed as Exhibit 99.1

4Disclosure under Item 8.01 Other Events

5Additional Exhibit 99.2 referenced

Current Report Details

Event Type

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

8.01

Other Events. On March 10, 2026, CRISPR Therapeutics AG (the “Company”) issued a press release announcing that it had commenced a private offering, subject to m

Other Event

$350.0M$550.0M

9.01

Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Press Release dated March 10, 2026, issued by CRISPR Therapeutics AG. 99.2 Press R

Exhibits Only

Source Document

Exhibits (3)

8-K

99.1

EX-99.1

99.2

EX-99.2